ArticleBMJ open2026
Effects of tegileridine versus sufentanil on postoperative nausea and vomiting in female patients undergoing laparoscopic cholecystectomy with a multimodal antiemetic approach based in Chengdu, China: protocol for a dual-centre randomised controlled trial.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPostoperative nausea and vomiting (PONV) remains one of the most common complications after laparoscopic cholecystectomy, especially in female patients faced with high baseline risk. Although multimodal antiemetic strategies are routinely used in perioperative care, opioid exposure remains an important contributor to PONV. Tegileridine, a novel G protein-biased μ-opioid receptor agonist, may provide effective analgesia with fewer gastrointestinal adverse effects than conventional opioids such as sufentanil. However, evidence on its role in preventing PONV in female patients undergoing laparoscopic cholecystectomy remains limited. METHODS AND ANALYSIS: This dual-centre, randomised controlled trial will enrol 148 female patients undergoing elective laparoscopic cholecystectomy at two tertiary hospitals in Chengdu, China. Participants will be randomly assigned individually (1:1 ratio) to receive either tegileridine-based or sufentanil-based perioperative analgesia within a standardised multimodal antiemetic framework. Randomisation will be centrally performed using a web-based system with allocation concealment. Participants, postoperative outcome assessors and data analysts will remain blinded to treatment allocation. The primary outcome will be the overall incidence of PONV within 24 hours after surgery. Secondary outcomes will include the incidence and severity of nausea and vomiting at predefined postoperative time points, pain scores, use of rescue analgesic and antiemetic medication, quality of recovery, opioid-related adverse events and recovery-related time-dependent outcomes. ETHICS AND DISSEMINATION: This study has been approved by the ethics committees of West China Hospital, Sichuan University and West China Tianfu Hospital, Sichuan University (ethical review no. 1775.2025). Written informed consent will be obtained from all participants before enrolment. The findings will be disseminated through peer-reviewed publications and academic conferences. TRIAL REGISTRATION NUMBER: ChiCTR2500111528.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.